Buscar
Mostrando ítems 1-10 de 43
Eficacia y seguridad de la vacuna contra COVID-19 de la Universidad de Oxford/AstraZeneca: AZD1222
(Instituto Nacional de Salud, 2021-09)
La vacuna contra la COVID-19 desarrollada por Universidad de Oxford/AstraZeneca es una vacuna de tipo
vector viral denominada AZD1222, que se ha comercializado bajo los nombres de Vaxzevria o Covishield
(Producida por ...
Eficacia y seguridad de la vacuna contra COVID-19 de la Universidad de Oxford/AstraZeneca: AZD1222
(Instituto Nacional de Salud, 2021-09)
La vacuna contra la COVID-19 desarrollada por Universidad de Oxford/AstraZeneca es una vacuna de tipo
vector viral denominada AZD1222, que se ha comercializado bajo los nombres de Vaxzevria o Covishield
(Producida por ...
SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes
(2022)
Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters.
From a population-based study performed ...
Evaluation of hydrogen peroxide efficacy against AZD1222 chimpanzee adenovirus strain in the recombinant COVID-19 vaccine for application in cleaning validation in a pharmaceutical manufacturing industry
(2021)
Este estudo teve como objetivo avaliar o desempenho do vapor de peróxido de hidrogênio (HPV) na inativação da cepa vacinal de adenovírus chimpanzé AZD1222 utilizada na produção de vacina recombinante COVID-19 para aplicação ...
Adverse event profile of ChAdOx1 nCoV-19 vaccine (AZD1222) in Brazil: Comparison between Bio-Manguinhos/Fiocruz post-marketing surveillance database and clinical trials
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2022)
Virucidal activity evaluation of hydrogen peroxide wipes against the AZD1222-chimpanzee adenovirus in active pharmaceutical ingredient and the recombinant COVID-19 vaccine
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2022)